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Key Points
•High-dose chemother-
apy increased early re-
mission and overall and
relapse-free survival
compared with
conventional-dose
chemotherapy.
• Allograft performance
in high-risk patients and
some standard-risk pa-
tients significantly im-
proved survival.
Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the
early complete remission (CR) rate in acute myelogenous leukemia (AML) compared
with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study
enrolled 574 patients (age, 16-73 years; median, 52 years) who were randomly assigned to
ICE (n 5 286 evaluable) or sHD (2 weekly 3-day blocks with cytarabine 2 g/m2 twice a day
for 2 days plus idarubicin; n 5 286 evaluable). Responsive patients were risk-stratiﬁed for
a second randomization. Standard-risk patients received autograft or repetitive blood
stem cell-supported high-dose courses. High-risk patients (and standard-risk patients not
mobilizing stem cells) underwent allotransplantation. CR rates after 2 induction courses
were comparable between ICE (80.8%) and sHD (83.6%; P 5 .38). sHD yielded a higher
single-induction CR rate (69.2% vs 81.5%; P 5 .0007) with lower resistance risk (P , .0001),
comparable mortality (P5 .39), and improved 5-year overall survival (39% vs 49%; P5 .045)
and relapse-free survival (36% vs 48%; P 5 .028), despite greater hematotoxicity delaying
or reducing consolidation blocks. sHD improved the early CR rate in high-risk AML (odds ratio,
0.48; 95% conﬁdence interval [CI], 0.31-0.74; P 5 .0008) and in patients aged 60 years and less
with de novo AML (odds ratio, 0.46; 95% CI, 0.27-0.78; P 5 .003), and also improved overall/
relapse-free survival in the latter group (hazard ratio, 0.70; 95% CI, 0.52-0.94; P 5 .01), in
standard-risk AML, and postallograft (hazard ratio, 0.61; 95% CI, 0.39-0.96; P 5 .03). sHD was
feasible, effectively achieved rapid CR, and improved outcomes in AML subsets. This study is
registered at www.clinicaltrials.gov as #NCT00495287.
Introduction
In adult acute myelogenous leukemia (AML), intensive induction chemotherapy is a standard approach
for achieving complete remission (CR),1 as defined by an international panel of experts.2 CR enables
the delivery of consolidation chemotherapy and/or allogeneic hematopoietic stem cell transplantation
(HSCT), which can prolong survival and cure the disease.1,3-5 Because CR is the starting point for
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curative treatment and a strong predictor of survival, it is important
to optimize the induction chemotherapy protocol.
Several groups have attempted to improve the standard “317”
CR induction regimen, which includes 3 days of daunorubicin and
7 days of conventional-dose cytarabine.6 Large randomized trials
have tested high-dose (HD) daunorubicin (or equivalent idarubicin),7-12
HD cytarabine,13-17 and nucleoside analogs,18-20 with variable
results. HD cytarabine is a mainstay of postremission consolida-
tion,21 and is widely used in relapsed/refractory AML. The use of HD
cytarabine-based programs improved the rates of CR and relapse-
free survival (RFS) in the Australasian Leukemia Study Group trial,13
as well as among patients aged 45 years or younger in the European
Organization for Research and Treatment of Cancer-Gruppo Italiano
Malattie Ematologiche dell’Adulto AML 12 study,17 but not in 3
other trials.14,16,20
The German AML Study Group (AMLSG) developed an effective
sequential HD regimen for relapsed/refractory AML, which includes
cytarabine plus either mitoxantrone or idarubicin.22-25 Up-front
use of this regimen with dose-dense HD cytarabine-mitoxantrone
(HAM)–HAM double induction (cytarabine 3 g/m2 and mitoxan-
trone) yielded 83% CR and 7% persistent leukemia.26 A trial
extension in the German collaborative intergroup project yielded
76% CR and 13% refractory AML. A parallel East Germany
Hematology-Oncology Group trial (NCT01414231) compared
continuous vs infusional sequential cytarabine (2 g/m2) and
achieved 74% CR and 14% resistance, showing no improvement
over standard ICE (idarubicin-cytarabine-etoposide) induction.27
The Northern Italy Leukemia Group performed a phase 2 study
using a sequential HD regimen for patients resistant to standard
ICE induction (NCT00400673). Of 95 treated patients, 57%
achieved CR, with similar rates across different clinico-cytogenetic
risk groups.28 Long-term outcome was significantly improved among
patients who entered early CR during course 1 (ie, before receiving
any HD chemotherapy).29 Achieving CR after a single course is
considered a favorable prognostic factor,30-34 with rare excep-
tions.35 In 1 large retrospective study (n5 8907), late CR achieved
after reinduction therapy predicted significantly poorer outcome.31
Early responders are typically easier to manage, curable with
shorter hospitalization and fewer complications, and can receive
earlier postremission therapy and HSCT.
In the present randomized trial, we compared ICE with sequential
HD schedule (sHD) in untreated patients, with the aim of improving
the early CR rate and evaluating any favorable effect on survival.
Patients and methods
Patients
All patients with newly diagnosed AML or high-risk (HR) myelodysplasia
(MDS; marrow blasts . 10%) who presented at the participating
institutions during the study period were registered for an outcome
assessment project and screened for trial eligibility. Eligible patients
had AML or HRMDS that was de novo, secondary to cancer chemo-
radiotherapy, or developed in a background of MDS or chronic
myeloproliferative neoplasm, excluding acute promyelocytic leukemia.
Only patients at least 16 years old were included. Because of the
high AML prevalence among elderly individuals, we did not initially set
an upper age limit for study inclusion, but rather enrolled older
patients who were deemed fit enough to receive study medications.
Thus, this trial included patients older than 65 years until a study
amendment set an age limit of 65 years. All included patients gave
their written informed consent. The study was approved by the
Institutional Review Boards of the 17 participating Northern Italy
Leukemia Group sites, registered as NCT00495287, and conducted
in accordance with the Declaration of Helsinki.
AML diagnosis
AML diagnosis was locally confirmed by cytogenetics and immuno-
phenotype, following the standard criteria adopted for this study
(supplemental File 1). Patient enrollment required central review of
diagnostic bone marrow slides and trephine biopsy. FLT3,36 NPM1,37
CEBPA, and MLL mutations were investigated at the Laboratorio
“Paolo Belli,” Department of Hematology, Bergamo Hospital, and
the Institute of Hematology, Perugia University.
Trial design and CR induction, randomization 1
The study protocol (supplemental File 2), its background (supple-
mental File 3.1), and the trial amendments (supplemental File 3.2) are
reported online. Amendment 3 limited enrollment to patients 65 years
old or younger, as insufficient accrual of older patients (n5 35) led to
inconclusive results in randomization 1. For CR induction (random-
ization 1), patients were stratified according to age (#60
or .60 years) and were randomly assigned to undergo standard
ICE or sHD. Patients who achieved CR underwent risk-adapted
postremission therapy (Figure 1). Both induction groups received
a cumulative idarubicin dose of 36 mg/m2, previously defined in a
dose-escalation study.38 All patients received granulocyte colony-
stimulating factor (G-CSF), which is safe and effective in reducing
absolute neutropenia duration and related complications after
chemotherapy.39,40 In both study groups, G-CSF administration
started on day 11 (ie, after the second sHD block). The current
sHD regimen was patterned after the administration schedule of
cytarabine 3 g/m2 (more activity than 1 g/m2) developed by the
AMLSG for relapsed/refractory AML.23 To limit toxicity, particularly
the risk for early death because of infection associated with
cytarabine 3 g/m2, patients in the sHD group received cytarabine
2 g/m2 (1 g/m2 if .65 years of age).24 Adopting a 2-step induction
strategy derived from the previous trial, patients who were unresponsive
to course 1 received an augmented sHD course with cytarabine 3 g/m2
(2 g/m2 when .60 years of age) or other salvage therapy at the
discretion of the treating physicians. Patients who did not achieve
CR after 2 courses were removed from the study, as were patients
who were assigned to HSCT as salvage instead of chemotherapy.
Risk-oriented postremission therapy and random 2
Patients who achieved CR were risk stratified according to
cytogenetics,41-43 FLT3mutations, and selected clinical risk factors
(HR MDS, AML secondary to MDS/myeloproliferative neoplasm,
therapy-related AML, minimally differentiated AML, erythroleukemia,
megakaryoblastic leukemia, primary isolated granulocytic sarcoma,
white blood cell count, .50 3 109/L, and late CR). The HR group
comprised patients with unfavorable or unknown cytogenetics or
with intermediate/normal cytogenetics plus either FLT3 and MLL
mutations or another clinical risk feature. This group was scheduled to
receive HSCT from siblings or unrelated donors. The standard-risk (SR)
group comprised patients with favorable cytogenetics and those with
intermediate/normal cytogenetics and lacking FLT3 mutations or
any clinical risk factors. SR patients, along with HR patients unable
to receive allogeneic HSCT, underwent randomization 2. Some
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patients received intravenous busulfan (BU; 0.8 mg/kg every 6 hours
for 4 days) and cyclophosphamide (CY; 60 mg/kg daily for 2 days),
followed by blood stem cell autotransplantation. Others underwent
repetitive blood stem cell-supported HD chemotherapy courses
(cumulative cytarabine 20 g/m2 plus idarubicin 16 mg/m2). Blood
stem cells were mobilized with intermediate-dose (ID) cytarabine and
G-CSF. Patients who displayed poor mobilization (,2 3 106/kg
CD341) and patients older than 65 years were consolidated with
age-adapted ID chemotherapy courses (Figure 1) or were consid-
ered for HSCT despite SR status.
Objectives, definitions, and statistics
The primary study endpoint was whether sHD significantly reduced
the risk for chemoresistance and increased the early CR rate
compared with standard ICE chemotherapy. In the prior study, 22%
of patients exhibited ICE-resistant AML (n5 129/581), of whom 57%
were effectively rescued by sHD (n5 54/95)28 (supplemental File 3.1).
Extrapolating these data for the sample size calculation for the
current study, we estimated that we needed at least 250 patients
per group to demonstrate a 38% relative risk reduction (RRR) for
unresponsive disease, with sHD given as investigational course 1,
with 80% power and 0.05 a error. We used standard endpoint
definitions. CR was defined as more than 1.0 3 109/L neutrophils
and at least 100 3 109/L platelets, regenerating marrow with
evidence of trilineage hematopoiesis, blast cells less than 5%
(no Auer rods), and no extramedullary leukemia. CR included CRwith
incomplete hematological recovery, defined as fewer than 1.03 109/L
neutrophils and/or fewer than 1003 109/L platelets.5 Resistant AML
was defined as less than CR/CR with incomplete hematological
recovery, with persistence of AML blasts in the bone marrow and/or
blood smears. Response was assessed by evaluation of bone
marrow on day 28, or later if clinically indicated. Day 14 bone marrow
examination was not planned in this study.
Randomization 2 compared long-term RFS (time from date of CR
to relapse or death in remission) between SR treatment groups.
Secondary objectives included overall survival (OS; from study
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Figure 1. Design of the Northern Italy Leukemia Group AML trial 02/06. ICE was compared with sHD induction chemotherapy. After a common 2-step CR
induction and early consolidation phase, patients received 1 of 2 types of final consolidation, depending on risk. Patients at HR received allogeneic HSCT. Patients
at SR, 65 years of age or younger, and mobilizing blood stem cells underwent a second randomization to either standard BU-CY-conditioned autologous HSCT or
up to 3 repetitive blood stem cell-supported HD courses, denoted “A20” after the cumulative cytarabine (arabinosylcytosine, A) dose of 20 g/m2. SR patients unable
to proceed to HD consolidation could receive allogeneic HSCT, and HR patients unable to receive HSCT could undergo HD consolidation. Patients older than
65 years and/or not mobilizing blood stem cells underwent 1 to 2 additional age-adapted ID consolidation courses, denoted “A15,” “A10,” or “A8” after the
cumulative cytarabine dose (dashed line).
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enrollment to death), event-free survival (from enrollment to induction
failure, relapse, or death in remission),2 cumulative incidence of
relapse, and the feasibility and efficacy of study treatments in
different age and risk groups. To evaluate prognostic effects not
assessable by the original Northern Italy Leukemia Group risk
classification, we performed post hoc prognostic analysis, using the
European LeukemiaNet (ELN) 2010 genetic risk stratification,44
including the results of centralized analysis of CEBPA and MLL
mutations in cryopreserved AML cells. Therapy-related complica-
tions were gradedusing common toxicity criteria (CTC; http://ctep.cancer.
gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf).
Statistical analyses were performed following the intention-to-treat
principle. Baseline patient characteristics were compared between
treatment groups, using a x2 or Fisher’s exact test (categorical
variables) or the Mann-Whitney U test (continuous variables). We
assessed the relationship between CR achievement and study
group, using the x2 test. The RRR indicated the proportion of
ICE failures (resistance/death) that could have been avoided
with sHD. Survival was estimated using the Kaplan-Meier method,
and long-term outcomes compared using the log-rank test. Relapse
incidence was assessed using cumulative incidence function,
considering death as a competing event. Subgroup and multivar-
iate analyses with logistic regression and Cox models were
performed to estimate odds ratios with 95% confidence intervals
(CIs) for CR achievement, and hazard ratios with 95% CIs for
survival outcomes. In multivariate analysis, HSCT was considered
1354 Patients registered
574 Trial patients
(Random 1)
780 No trial patients
118 APL diagnosis
264 Not eligible
344 Medical decision
301 Elderly/unfit
43 Other
43 Refusal
6 Early death
5 Other
286 Evaluable (Outcome)
109 Patients alive
84 In first CR
25 Not in first CR
123 Patients relapsed
169 Patients died
22 In first CR
8 Patients unknown status
231 CR patients
7 Did not have consolidation/HSCT
23 Had early consolidation only
99 Had final consolidation
44 Entered Random 2
23 Had autologous HSCT
18 Had HD chemotherapy
3 Did not have assigned therapy
55 Did not enter Random 2
5 Had autologous HSCT
6 Had HD chemotherapy
44 Had ID chemotherapy
102 Had allogeneic HSCT
287 Assigned to ICE arm
1 Consent withdrawal
1 Early death
1 Did not have assigned therapy
284 Had assigned therapy
286 Evaluable
198 CR
16 ED
72 NR
46 Had salvage
33 CR
26 Off study
287 Assigned to sHD arm
1 Switched to TKI (Ph+)
1 Early death
2 Did not have assigned therapy
283 Had assigned therapy
286 Evaluable (Outcome)
137 Patients alive
120 In first CR
17 Not in first CR
102 Patients relapsed
144 Patients died
20 In first CR
5 Patients unknown status
239 CR patients
10 Did not have consolidation/HSCT
34 Had early consolidation only
104 Had final consolidation
39 Entered Random 2
16 Had autologous HSCT
23 Had HD chemotherapy
65 Did not enter Random 2
6 Had autologous HSCT
6 Had HD chemotherapy
53 Had ID chemotherapy
91 Had allogeneic HSCT
286 Evaluable
233 CR
21 ED
32 NR
17 Had salvage
6 CR
15 Off study
Figure 2. CONSORT diagram illustrating patient selec-
tion, study flow, successive treatment steps, and patient
outcome, according to the randomization group. APL,
acute promyelocytic leukemia; ED, early death; NR, nonre-
sponder; TKI, tyrosine-kinase inhibitor.
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Table 1. Demographics andmain clinico-diagnostic characteristics of 572 patients randomly assigned to receive induction chemotherapy with
either ICE or sHD
Patient characteristics All patients (N 5 572) ICE (N 5 286) sHD (N 5 286) P
Age (at randomization), median (range), y 52 (16-73) 53 (16-73) 50 (18-72) .34
.60 y, n (%) 140 (24.5) 73 (25.5) 67 (23.4) .55
Sex
Male, n (%) 301 (52.6) 156 (54.5) 145 (50.7) .35
Diagnosis, n (%)
AML morphological subtype* .82
SR 478 (83.6) 240 (83.9) 238 (83.2)
HR 94 (16.4) 46 (16.1) 48 (16.8)
HR MDS 6 (1.0) 3 (1.0) 3 (1.0)
AML category .80
De novo 494 (86.4) 248 (86.7) 246 (86.0)
Non de novo† 78 (13.6) 38 (13.3) 40 (14.0)
ECOG PS, n (%) .01
0 292 (51.1) 130 (45.5) 162 (56.6)
1 232 (40.6) 134 (46.9) 98 (34.3)
2 42 (7.3) 19 (6.6) 23 (8.0)
3 6 (1.0) 3 (1.0) 3 (1.0)
Clinical features, n (%)
Hepatomegaly 42 (7.3) 20 (7.0) 22 (7.7) .74
Splenomegaly 65 (11.4) 29 (10.1) 36 (12.6) .35
Extramedullary involvement 71 (12.4) 34 (11.9) 37 (12.9) .70
Hematology, median (range)
Hemoglobin, g/dL 9.1 (3-15.8) 9.3 (3.6-14.8) 8.9 (3-15.8) .82
WBC, 3109/L 10.5 (0.5-990) 12.3 (0.5-990) 9.2 (0.6-260) .10
Platelets, 3109/L 53 (2-852) 53 (2-815) 53.5 (3-852) .74
Peripheral blood blast cells, % 47.5 (0-100) 46 (0-100) 48 (0-100) .94
Bone marrow blast cells, % 77 (0-100) 80 (6-100) 74.5 (0-100) .18
Cytogenetics, n (%)
Favorable 52 (9.1) 23 (8.0) 29 (10.1) .59
t(8;21)‡ 20 (3.5) 10 (3.5) 10 (3.5)
inv(16)§,‖ 32 (5.6) 13 (4.5) 19 (6.6)
Intermediate
Normal karyotype 272 (47.6) 142 (49.7) 130 (45.5) .31
Abnormal{ 9 (1.6) 4 (1.4) 5 (1.7) .08
Adverse# 170 (29.7) 82 (28.7) 88 (30.8) .52
Other 12 (2.1) 6 (2.1) 6 (2.1) 1.0
Unknown 57 (10.0) 29 (10.1) 28 (9.8) .88
After amendment 3 (September 2009), patients older than 65 years were no longer enrolled into the study.
1, gene rearrangement or mutation; ITD, internal tandem duplication; PM, point mutation; NILG, Northern Italy Leukemia Group; sHD, sequential HD cytarabine/idarubicin; WBC, white blood
cell count.
*HR: minimally differentiated AML, erythroleukemia, megakaryoblastic leukemia, undifferentiated/bilineal/biphenotypic acute leukemia, acute panmyelosis with myelofibrosis, myeloid sarcoma,
AML with multilineage dysplasia, HR MDS (marrow blast cells, 10%-20%); SR, all other morphological and diagnostic subsets.
†AML after myelodysplastic or chronic myeloproliferative syndromes, related to another therapy (chemotherapy/radiotherapy for another cancer), or preceded by an antecedent hematologic
disorder (unexplained cytopenia).
‡Total number with either method: 27/572 (4.7%).
§inv(16), t(16;16), del(16q).
‖Total number with either method: 42/572 (7.3%).
{Abnormalities included 16, 111, 113, 122, del(12p), t(9;11), -Y.
#Adverse abnormalities included 25/del(5q), 27/del(7q), t(11;19)/t(11q23), and MLL gene rearrangements, t(9;22), abn 3q,9q,11q,12p,20q,21q,17p, iso(17q), 18, 121, t(3;3), t(3;5);
inv(3), t(6;9), t(6;11), and complex karyotype with 3 or more unrelated clonal markers.
**Eleven patients with concurrent favorable and adverse cytogenetics were included in the adverse group, as per protocol design.
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a time-dependent variable. P values were 2-sided and not adjusted for
multiple comparison. The significance level was fixed at 5%. Statistical
analyses were performed with SAS software version 9.4.
Results
Patients
Figure 2 shows patient disposition and study flow. Between
January 2007 and March 2012, we registered and screened 1354
patients for eligibility, of whom 574 were enrolled and randomized.
Among these patients, 572 were evaluable: 286 in each study
group. Two trial patients were excluded from analysis: 1 withdrew
consent and 1 had Philadelphia-positive AML and was switched to
tyrosine kinase inhibitors. Five patients did not complete the
allocated treatment, including 2 in the ICE group (1 early death,
1 medical decision) and 3 in the sHD group (1 early death; 2 other
chemotherapy), but were included in the analysis based on
treatment intention. The median patient age was 52 years (range,
16-73 years). Diagnostic characteristics and HR proportions were
balanced between study groups, except that the sHD group
included a higher incidence of patients with an optimal perfor-
mance score (Table 1). Of the 1354 patients registered in the
prospective outcome study project, 780 were excluded from the
trial for the following reasons: diagnosis of acute promyelocytic
leukemia (n 5 118), trial ineligibility (n 5 264), medical decisions
related to higher age and/or clinical unfitness (n 5 209; median
age, 64 years; range, 19-89 years), refusal (n 5 43), early death
(n 5 6), unspecified reason (n 5 5), and (starting September
2009) age older than 65 years (n 5 135; supplemental File 3.2).
The outcomes of all 1354 registered patients are available online
(supplemental File 3.3).
CR induction and randomization 1 results
In randomization 1, the CR rate was significantly higher with sHD
(n5 233, 81.5%) than ICE (n5 198, 69.2%; P5 .0007) because
of a markedly lower incidence of refractory AML (11.2% vs 25.2%;
P , .0001) and a comparable early death rate (P 5 .39; Table 2).
sHD treatment yielded a RRR of 0.40 (95% CI, 0.19-0.55), matching
the predicted primary study endpoint (RRR, 0.38). Based on the
course 1 refractory responses, course 2 reinduction chemotherapy
was administered to 46/72 patients in the ICE-resistant group and
17/32 patients in the sHD-resistant group, achieving late CR in 33
(71.7%) and 6 (35.3%) patients, respectively, with augmented sHD
(n 5 25/36, 69.4%) or other chemotherapy (n 5 14/27, 51.9%).
After 2 induction courses, the overall CR rates were 80.8% in the
ICE group and 83.6% in the sHD group (P5 .38). In addition, CRwas
achieved in 12 of 13 course-1-resistant patients who underwent
off-study allogenic HSCT.
Table 1. (continued)
Patient characteristics All patients (N 5 572) ICE (N 5 286) sHD (N 5 286) P
Genetics, n (%)
MLL-rearrangement 24/397 (6.0) 10/200 (5.0) 14/197 (7.1) .65
FLT3-ITD1 103/569 (18.1) 55/284 (19.4) 48/285 (16.8) .58
FLT3-PM1 40/555 (7.2) 22/275 (8.0) 18/280 (6.4) .36
NPM11 167/551 (30.3) 87/277 (31.4) 80/274 (29.2) .68
CBFB-MYH111‖ 41/557 (7.4) 16/278 (5.8) 25/279 (9.0) .33
AML1/ETO1‡ 27/558 (4.8) 15/277 (5.4) 12/281 (4.3) .45
CEBPA1 19/361 (5.3) 8/182 (4.4) 11/179 (6.1) .60
NILG risk group, n (%) ** .13
SR 156 (27.3) 70 (24.5) 86 (30.1)
HR 416 (72.7) 216 (75.5) 200 (69.9)
ELN 2010 risk group, n (%) .56
Favorable 166 (29.0) 82 (28.7) 84 (29.4)
Intermediate 1 147 (25.7) 80 (28.0) 67 (23.4)
Intermediate 2 70 (12.2) 36 (1.6) 34 (11.9)
Adverse 135 (23.6) 60 (21.0) 75 (26.2)
Unknown 54 (9.4) 28 (9.8) 26 (9.1)
After amendment 3 (September 2009), patients older than 65 years were no longer enrolled into the study.
1, gene rearrangement or mutation; ITD, internal tandem duplication; PM, point mutation; NILG, Northern Italy Leukemia Group; sHD, sequential HD cytarabine/idarubicin; WBC, white
blood cell count.
*HR: minimally differentiated AML, erythroleukemia, megakaryoblastic leukemia, undifferentiated/bilineal/biphenotypic acute leukemia, acute panmyelosis with myelofibrosis, myeloid
sarcoma, AML with multilineage dysplasia, HR MDS (marrow blast cells, 10%-20%); SR, all other morphological and diagnostic subsets.
†AML after myelodysplastic or chronic myeloproliferative syndromes, related to another therapy (chemotherapy/radiotherapy for another cancer), or preceded by an antecedent hematologic
disorder (unexplained cytopenia).
‡Total number with either method: 27/572 (4.7%).
§inv(16), t(16;16), del(16q).
‖Total number with either method: 42/572 (7.3%).
{Abnormalities included 16, 111, 113, 122, del(12p), t(9;11), -Y.
#Adverse abnormalities included 25/del(5q), 27/del(7q), t(11;19)/t(11q23), and MLL gene rearrangements, t(9;22), abn 3q,9q,11q,12p,20q,21q,17p, iso(17q), 18, 121, t(3;3), t(3;5);
inv(3), t(6;9), t(6;11), and complex karyotype with 3 or more unrelated clonal markers.
**Eleven patients with concurrent favorable and adverse cytogenetics were included in the adverse group, as per protocol design.
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CR induction randomization 1 toxicity
In randomization 1, sHD more frequently led to blood cytopenia,
fever, and infections related to treatment-emergent toxicity, as well
as hepatic and metabolic complications, but did not increase early
mortality (Table 3). From treatment day 1, recovery to a neutrophil
count higher than 0.5 3 109/L took 21 days with ICE vs 27 days
with sHD (P, .0001), and recovery to a platelet count higher than
203 109/L took 21 days with ICE vs 29 days with sHD; P, .0001).
Infection rates were 82% with ICE and 90.5% with sHD (P 5 .003),
with sHD associated with high incidences of bacterial and Aspergillus
spp. etiology, sepsis, and pneumonia. Most hepatic, metabolic, and
cutaneous adverse events were CTC grade 2 or lower. Only 2 to 5
episodes in each CTC category scored higher with sHD than ICE.
Postremission therapy
As a result of greater myelosuppression and related toxicities,
significantly fewer patients with sHD completed early postremission
consolidation (n 5 166/239, 69.5%) compared with ICE patients
(186/231, 80.5%; P 5 .005). Compared with ICE, sHD required
longer intercycle intervals and displayed inferior CD341 blood cell
mobilization (supplemental File 3.4). Of the 470 total CR patients,
193 (41%; 20% of SR and 50% of HR; 102 ICE vs 91 sHD, P 5
.18) received allogeneic HSCT as their final treatment. Another 103
patients (22%; 41% of SR and 13% of HR) received HD treatment
under randomization 2, of whom 83were randomized and 80 actually
underwent either autologous HSCT or repetitive blood stem cell-
supported HD courses. Of the remaining patients, 97 (21%) received
ID chemotherapy courses, 60 (12.8%) underwent only early
consolidation because of early relapse or toxicity, and 17 (3.8%)
received no postremission therapy.
Long-term results
After a median follow-up of 4.9 years (range, 0.2-8.4 years), 204
patients (35.6%) were alive in first CR (84 ICE [29.3%] and 120
sHD [41.9%]; P 5 .002), 42 (7.3%) survived in second/later CR,
313 (54.7%) died, and 13 (2.3%) were lost to follow-up. The 5-year
cumulative incidences of relapse were 55% (ICE) and 44% (sHD;
P 5 .046). Compared with ICE, sHD was associated with improved
5-year OS (39% [median, 2.2 years] vs 49% [median, 4.5 years];
P 5 .045), 5-year event-free survival (29% [median, 1.2 years] vs
40% [median, 1.6 years]; P 5 .019), and 5-year RFS (36% [median,
1.5 years] vs 48% [median, 3.4 years]; P 5 .028; Table 2;
Figure 3). We further examined the survival effects of allogeneic
HSCT or randomization 2 therapy. When the 193 patients who
underwent allogeneic HSCT in first CR were censored at the
time of transplant, sHD no longer conveyed a detectable significant
survival advantage (supplemental File 3.5). However, when separately
considering the 2 study groups, sHD-treated patients (n 5 91)
Table 2. Main CR induction and trial results, according to randomization group
ICE group (n 5 286) sHD group (n 5 286) RRR*/hazard ratio (95% CI) P
CR induction course 1 (random 1), (%)
CR† 198 (69.2) 233 (81.5) 0.40 (0.19-0.55) .0007
NR 72 (25.2) 32 (11.2) ,.0001
ED 16 (5.6) 21 (7.3) .39
CR induction course 2, n/N (%)
CR 33/46 (71.7) 6/17 (35.3) 21.29 (23.09 to 20.28) .008
NR 12/46 (26.1) 11/17 (64.7) .008
ED 1/46 (2.2) 0 1.0
Total CR (courses 112), n (%)‡ 231 (80.8) 239 (83.6) 0.15 (20.22 to 0.40) .38
Relapse and survival estimates
5-y incidence of relapse (95% CI), % 55 (48-61) 44 (37-50) 0.77 (0.59-0.99) .046
5-y incidence of death in CR (95% CI), % 10 (6-14) 8 (5-12) 0.87 (0.48-1.60) .66
Overall survival
Median, y 2.2 4.5
5-y rate (95% CI), % 39 (33-45) 49 (42-55) 0.79 (0.63-0.99) .045
Survival of CR patients
Median, y 3.6 N/A
5-y rate (95% CI), % 46 (39-52) 54 (47-61) 0.81 (0.62-1.06) .12
Relapse-free survival
Median, y 1.5 3.4
5-y rate (95% CI), % 36 (29-42) 48 (41-54) 0.77 (0.60-0.97) .028
N/A, not achieved.
*Proportion of failures that would be avoided with sHD in patients treated with ICE.
†Treatment groups were well distributed by study center (n 5 17; P 5 .5). By Cochran-Mantel-Haenszel x2 test using center as stratification factor, the higher CR rate with sHD
at random 1 remained statistically significant (P 5 .001). Similarly, stratified Cox models confirmed the treatment effect on OS (hazard ratio, 0.78; 95% CI, 0.62-0.99; P 5 .041) and relapse-
free survival (hazard ratio, 0.75; 95% CI, 0.59-0.96; P 5 .022).
‡Including CR with incomplete hematological recovery: 3 in ICE group and 8 in sHD group (P 5 .12).
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exhibited significantly better posttransplantation outcomes than
ICE-treated patients (n 5 102): 5-year survival of 69% vs 55%
(P5 .06) and RFS of 66% vs 49% (P5 .03; supplemental File 3.6).
Finally, among randomization 2 patients (n 5 83 evaluable; 44 ICE
and 39 sHD), 5-year OS and RFS did not significantly differ between
the 2 groups (supplemental File 3.7.1). Projected RFS was 50%
(median, 2.6 years) in the blood stem cell-supported HD chemo-
therapy group (n 5 42, 103 total HD courses; median, 3 courses;
range, 1-3 courses) and 36% (median, 1.48 years) in the BU-CY
autotransplantation group (n 5 41; P 5 .31). We observed a trend
of better survival with repetitive HD courses than with autotrans-
plantation in patients with sHD (P 5 .05; supplemental File 3.7.2),
but no superiority compared with ICE-treated patients. Compared
with HR patients, SR patients had a higher 5-year RFS (51%
vs 30%; P 5 .03). Pancytopenic death rates were 2.4% with
autotransplantation vs 2.5% with HD courses (1% among 103 total
HD courses). The cumulative incidence of bacterial infections and
metabolic, neurologic, and cutaneous toxicity was greater in the
repetitive HD chemotherapy group (supplemental File 3.8).
Prognostic analysis
Early CR rates were significantly higher with sHD than ICE in
several groups, including the large reference group of patients aged
60 years or less with de novo AML, the HR AML group, adverse
genetic/cytogenetic subsets, and the NPM1 wild-type AML group
Table 3. Induction toxicity according to randomization group
Toxicity type
ICE group
(n 5 286)
sHD group
(n 5 286) P
Hematologic toxicity (recovery time), median
days (range) from treatment day 1
Neutrophil count, 3109/L
.0.5 21 (8-54) 27 (13-114) ,.0001
.1.5 (G-CSF stopped) 22 (10-57) 28 (14-66) ,.0001
Platelet count, 3109/L
.20 21 (10-58) 29 (15-76) ,.0001
.50 23 (11-56) 32 (17-90) ,.0001
Fever and infections (clinical picture and
etiology), n (%)
Fever .38°C 222 254 .0002
Days with fever, median (range) 5 (1-24) 5 (1-40)
FUO 121 (42.6) 121 (42.8) .97
Bacteremia 45 (15.8) 80 (28.3) .0004
Sepsis 40 (14.1) 63 (22.3) .01
Pneumonia 59 (20.8) 83 (29.3) .01
Other involved site 73 (25.7) 85 (30.0) .25
Gastrointestinal system 31 (10.9) 30 (10.6) .90
Skin 48 (16.9) 59 (20.8) .22
Urinary system 1 (0.4) 2 (0.7) .99
Central nervous system 1 (0.4) 3 (1.1) .61
Bacterial 77 (27.1) 122 (43.1) .0001
Gram1 56 (19.7) 94 (33.2) .0003
Gram2 28 (9.9) 44 (15.5) .04
Fungal 24 (8.5) 47 (16.6) .003
Aspergillus spp. 17 (6.0) 37 (13.1) .004
Proven 2 (0.7) 5 (1.8)
Probable 13 (4.6) 21 (7.4)
Possible 2 (0.7) 11 (3.9)
Candida spp. 3 (1.1) 7 (2.5) .33
Other 4 (1.4) 5 (1.8) .99
Parasitic 2 (0.7) 0 .48
Viral 15 (5.3) 16 (5.7) .84
Unknown 123 (43.3) 108 (38.2) .21
Other toxicity (type/organ),
CTC grading, n
Hemorrhage .16
Any grade 41 53
Grade .2 15 16
Cardiovascular system .87
Any grade 19 18
Grade .2 9 8
Coagulation .36
Any grade 12 8
Grade .2 8 6
Hepatobiliary system .01
Any grade 65 91
Grade .2 23 28
Table 3. (continued)
Toxicity type
ICE group
(n 5 286)
sHD group
(n 5 286) P
Metabolism .04
Any grade 51 70
Grade .2 18 22
Kidney .28
Any grade 9 5
Grade .2 3 3
Amylase 1.0
Any grade 4 2
Grade .2 1 1
Central/peripheral nervous system .78
Any grade 7 6
Grade .2 2 3
Gastrointestinal system .42
Any grade 125 134
Grade .2 39 46
Skin .0003
Any grade 37 71
Grade .2 5 7
Lungs .13
Any grade 25 36
Grade .2 10 18
Allergy .73
Any grade 19 21
Grade .2 2 4
FUO, fever of unknown origin
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(Figure 4). Although the sHD group had a higher incidence of
favorable Eastern Cooperative Oncology Group performance score
(ECOG PS 0-1), this regimen was associated with an improved
early CR rate even among patients with an ECOG PS higher than 1.
Some smaller patient populations showed nearly significant
(P5 .05-.09) CR differences between treatments, including patients
with HR morphological variants, high leukocyte counts, age older
than 60 years, and/or non de novo AML. The assumption that an
improved early CR rate would positively affect OS was validated in
both SR and HR groups (supplemental File 3.9), excluding center-
related effects on early CR rate, OS, and RFS (Table 2). sHD
improved OS and/or RFS in patients aged 60 years or younger with
de novo AML, with SR AML, and with core-binding factor-positive
AML. Post hoc analysis with the ELN 2010 genetic risk stratification
revealed that sHD improved OS and/or RFS in the favorable group,
including patients with the NPM1-mutated/FLT3 wild-type genotype
or mutated CEBPA with a normal karyotype other than core-binding
factor AML (supplemental File 3.10).
Multivariate analysis including randomization 1 chemotherapy and
the allogeneic HSCT results described earlier confirmed that both
sHD induction chemotherapy and allogeneic HSCT had independent,
favorable, prognostic effects on survival. This effect was not detectable
with autotransplantation in patients entering randomization 2
(supplemental File 3.7.2). Older age, poor ECOG performance
score, intermediate/adverse cytogenetics, and FLT3 mutations
negatively affected survival probability, and NPM1 mutations were
consistently associated with better outcome (Table 4). We repeated
this analysis with the study risk model and the ELN 2010 genetic risk
stratification. After removing the single risk factors included in either
risk classification, both sHD regimen and the SR or ELN favorable risk
profile were associated with better CR, OS, and RFS.
Discussion
In this randomized study, we compared the sHD regimen with
standard ICE chemotherapy, which was considered at least
as effective as a HD daunorubicin “317” regimen for inducing
CR in adult AML.9,11 This controlled study evolved from a prior
AML investigation in which we tested sequential HD reinduction
for ICE-unresponsive patients,29,38 obtaining similar results
across all cytogenetic risk groups,28 and evaluated blood stem
cell-supported HD consolidation courses (NCT00400673) in
lieu of autotransplantation.45-47
P = .0453
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Figure 3. Kaplan-Meier survival analyses, according to the randomization group. (A) OS. (B) Event-free survival (EFS). (C) RFS. (D) Cumulative incidence of relapse (CIR).
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Our present results indicated that sHD yielded a significantly
better early induction response and survival than ICE. This study
included 572 evaluable patients aged at least 16 years (median
age, 52 years). More than 20% had very HR AML or HR MDS
and/or were aged older than 60 years, and more than 70% were
classified as HR according to the mixed functional clinico-
cytogenetic prognostic model used to distinguish between
patients eligible for allogeneic HSCT (HR) and others (SR). The
primary study endpoint (CR after course 1) showed therapeutic
benefit with sHD (early CR of 81.5% vs 69.2%; P 5 .0007) that
was attributable to a reduction of chemo-resistant AML from 25%
to 11%. The sHD and ICE groups exhibited comparable early
mortality, consistently below 10% and lower than reported in
German trials with similar regimens.14,26 After confirming these
results in most HR subsets, including patients with adverse ECOG
PS, we further demonstrated the feasibility of the current sHD
schedule. Although sHD lacked double induction with recycling on
day 21, as in the AMLSG trial,48 it did not favor higher resistance
rates. After 23 ICE-resistant patients entered CR with augmented
sHD, the gap between study groups (resulting from early CR) was
eventually closed. The prognostic advantage related to early CR
was confirmed by comparative survival analysis including late CR
patients. Retreatment of sHD-resistant patients was more difficult,
with poor results after augmented sHD. These very HR patients
should be considered for new experimental therapies and/or
immediate HSCT salvage.
Induction mortality was not higher with sHD, but sHD showed
higher hematologic and infectious toxicity than ICE, which hampered
postremission therapy, contributing to deficient patient accrual for
randomization 2. However, despite the trend of inferior transplantabil-
ity, sHD provided a lower relapse incidence and better RFS than the
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Figure 4. Forest plot of study groups. Effects of treatments on CR and OS, according to the main patient and disease characteristics.
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Table 4. Multivariate analysis of factors that influence CR, OS, and RFS, based on study group, individual prognostic variables including key
therapeutic steps (study group, allogeneic HSCT), and combined risk classification models (prospective study classification and post hoc
ELN 2010 risk stratification)
All patients Complete remission Overall survival Relapse-free survival
N CR, n (%) OR (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Individual prognostic factors
Study group
ICE 286 231 (80.8) 1.00 1.00 1.00
sHD 286 239 (83.6) 2.11 (1.38-3.23) .0006 0.71 (0.57-0.89) .004 0.70 (0.55-0.89) .004
HSCT*
No 379 — — — 1.00 1.00
Yes 193 — — — 0.33 (0.25-0.44) ,.0001 0.32 (0.23-0.43) ,.0001
Age, y
#45 179 163 (91.1) 1.00 1.00 1.00
45-60 253 209 (82.6) 0.65 (0.38-1.11) .11 1.25 (0.93-1.69) .14 0.93 (0.69-1.25) .62
.60 140 98 (70.0) 0.50 (0.28-0.90) .02 1.42 (1.03-1.95) .03 0.81 (0.57-1.16) .25
Sex
Male 301 245 (81.4) 1.09 (0.71-1.68) .69 0.84 (0.67-1.06) .15 0.76 (0.59-0.98) .04
Female 271 225 (83.0) 1.00 1.00 1.00
Morphological AML subtype
SD 478 403 (84.3) 1.00 1.00 1.00
HR 94 67 (71.3) 0.62 (0.37-1.06) .08 1.12 (0.83-1.53) .46 1.14 (0.79-1.65) .49
AML category
De novo 494 418 (84.6) 1.00 1.00 1.00
Non de novo 78 52 (66.7) 0.63 (0.35-1.11) .10 1.39 (1.00-1.92) .05 1.48 (0.99-2.19) .05
ECOG PS
0-1 524 438 (83.6) 1.00 1.00 1.00
2-3 48 32 (66.7) 0.48 (0.23-1.02) .05 1.26 (0.85-1.85) .25 0.85 (0.52-1.39) .53
Hepatosplenomegaly
No 487 397 (81.5) 1.00 1.00 1.00
Yes 85 73 (85.9) 1.49 (0.77-2.88) .23 1.34 (0.97-1.85) .08 1.58 (1.14-2.20) .006
WBC count, 3109/L
#50 443 365 (82.4) 1.00 1.00 1.00
.50 129 105 (81.4) 0.60 (0.33-1.07) .08 1.35 (1.01-1.82) .04 1.33 (0.96-1.82) .08
Cytogenetics
Favorable 52 50 (96.2) 1.00 1.00 1.00
Intermediate 281 246 (87.5) 0.20 (0.05-0.74) .01 2.53 (1.44-4.45) .001 1.91 (1.16-3.14) .01
Adverse 170 118 (69.4) 0.10 (0.03-0.36) .0005 5.63 (3.22-9.84) ,.0001 4.68 (2.80-7.83) ,.0001
Other 12 11 (91.7) 0.22 (0.03-1.62) .13 5.46 (2.27-13.15) .0002 3.80 (1.57-9.15) .003
Genetics
FLT3-ITD2 466 380 (81.5) 1.00 1.00 1.00
FLT3-ITD1 103 88 (85.4) 0.52 (0.28-0.97) .03 1.90 (1.40-2.57) ,.0001 1.88 (1.36-2.62) .0002
NPM1 wild-type 384 299 (77.9) 1.00 1.00 1.00
NPM1 mutated 167 152 (91.0) 4.52 (2.40-8.55) ,.0001 0.56 (0.42-0.76) .0001 0.64 (0.47-0.86) .003
Variations in the prognostic significance of individual risk factors outside the combined risk models are reported in the footnotes
OR, odds ratio.
*Time-dependent variable.
†The study risk classification incorporated: morphological AML subtype, AML category, hepatosplenomegaly, WBC, FLT3 mutations, and cytogenetics. In addition to SR risk class,
the modified prognostic model identified significant associations for improved CR (sHD group, P 5 .0008; age #60 years, P 5 .01; mutated NPM1, P , .0001), OS (HSCT, P , .0001; sHD
group, P 5 .05; mutated NPM1, P 5 .0006), and RFS (HSCT, P , .0001; sHD group, P 5 .003; mutated NPM1, P 5 .007). All other factors did not reach statistical significance (P . .05).
‡The ELN 2010 risk stratification incorporated: cytogenetics and genetics. In addition to the favorable risk class, the modified prognostic model identified significant associations for improved
CR (sHD group, P 5 .0004; age # 60 years, P 5 .03), OS (HSCT, P , .0001; sHD group, P 5 .003; no hepatosplenomegaly, P 5 .009; WBC, #50 3109/L, P 5 .02), and RFS (HSCT,
P , .0001; sHD group, P 5 .001; no hepatosplenomegaly, P 5 .0002; WBC, #50 3109/L, P 5 .02). All other factors did not reach statistical significance (P . .05).
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control group, consistent with the idarubicin/HD cytarabine/fludarabine
group of the Medical Research Council 15 trial.49 These results
suggested that early treatment intensity had an overall higher
effect than the number and interval of subsequent chemotherapy
courses. Both the current sHD and idarubicin/HD cytarabine/
fludarabine regimens included idarubicin plus cytarabine 2 g/m2,
with G-CSF, and the latter regimen added fludarabine.49,50 Together,
these findings suggest that sHD may be a valid alternative to the
classic “317” or ICE regimens for inducing early CR, particularly
in HR patients, and to standard reinduction for patients un-
responsive to a conventional first course, in keeping with recent
ELN recommendations.1
Separate analysis was required to assess suitability for allogeneic
HSCT and its effects. HSCT was applicable to 50% of HR patients,
and multivariate analysis confirmed that HSCT was an essential
component of curative treatment of many of these patients.
However, sHD patients had a significantly better posttransplanta-
tion course than ICE patients, indicating a positive interaction
between HD induction and postinduction HSCT. Recent HSCT
studies have demonstrated the usefulness of MRD analysis for
predicting the risk for transplantation failure.51-53 Our present
randomization 1 results might suggest that sHD-treated patients
may harbor less residual AML cells before HSCT compared with
ICE-treated patients. Although a formal pretransplantation MRD
study was not planned, at randomization 1, we performed an
immunophenotypic study of early peripheral blast cell clearance.54
These data will be separately reported, and could confirm that the
sHD regimen had greater activity in achieving early blast cell
reduction.
One main limitation of this study was that induction course 2
was not delivered as homogeneously as planned. Among course-
1-resistant patients, 43% did not receive the augmented sHD
regimen because of medical decisions. However, this finding
did not affect the analysis of randomization 1 results and did not
hamper the outcome comparison between early vs late CR
patients. In addition, CR was not centrally assessed but was
evaluated using standard criteria.5 Another limitation was that
randomization 2 failed because of lower-than-expected patient
accrual. This step required the harvest of 2 to 63 106/kg CD341
blood cells, which was successful in only 45.9% of CR cases.
We previously adopted the use of repetitive HD consolida-
tion courses, supported with 1 to 2 3106/kg CD341 blood
stem cells (NCT00400673), to avoid prolonged pancytopenia-
related complications and ensure dose-dense consolidation55,56
compared with similarly effective schedules.57 Compared with
BU-CY-conditioned autotransplantation, we found that the HD
consolidation modality was feasible, with minimal mortality risk,
although infectious morbidity was increased as a result of
the cumulative effects of multiple HD courses. This type of
consolidation preserved fertility and showed noninferior outcomes
compared with autotransplantation. As a consequence, we consider
this protocol for younger patients who are excluded from
allogeneic HSCT.
Another limitation of this study was that we lacked details regarding
new highly relevant genetic markers.58,59 Nevertheless, our univariate
and multivariate prognostic analyses revealed factors associated
with the best outcomes. We defined HR categories according to
cytogenetics (with results comparable to other adult AML series),
adverse clinical characteristics, and FLT3 mutations. We also
studied NPM1, MLL, and CEPBA gene mutations according to
the ELN 2010 genetic risk stratification, which allowed analysis
refinements in many cases. Both approaches confirmed that sHD
was superior to ICE in achieving CR (particularly in HR subsets) and
prolonging OS and RFS. The best results were observed in SR or
favorable-risk (ELN) groups, and in the typical subset of patients
aged 60 years or younger with de novo AML. The improved CR rate
with sHD in the HR group did not affect survival in the general intention-
to-treat analysis. However, this combination provided high RFS and
survival rates in the subgroup of CR patients proceeding to HSCT.
Table 4. (continued)
All patients Complete remission Overall survival Relapse-free survival
N CR, n (%) OR (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Risk stratification models
Study risk classification†
SR 156 145 (92.9) 1.00 1.00 1.00
HR 416 325 (78.1) 0.31 (0.18-0.55) ,.0001 3.52 (2.58-4.80) ,.0001 3.22 (2.37-4.38) ,.0001
ELN 2010 risk stratification‡
Favorable 166 159 (95.8) 1.00 1.00 1.00
Intermediate 1 147 119 (81.0) 0.18 (0.09-0.39) ,.0001 3.55 (2.46-5.11) ,.0001 2.78 (1.95-3.95) ,.0001
Intermediate 2 70 58 (82.9) 0.21 (0.09-0.52) .0006 3.81 (2.46-5.90) ,.0001 4.53 (2.95-6.96) ,.0001
Adverse 135 92 (68.1) 0.11 (0.05-0.24) ,.0001 6.88 (4.73-9.99) ,.0001 5.69 (3.89-8.33) ,.0001
Variations in the prognostic significance of individual risk factors outside the combined risk models are reported in the footnotes
OR, odds ratio.
*Time-dependent variable.
†The study risk classification incorporated: morphological AML subtype, AML category, hepatosplenomegaly, WBC, FLT3 mutations, and cytogenetics. In addition to SR risk class,
the modified prognostic model identified significant associations for improved CR (sHD group, P 5 .0008; age #60 years, P 5 .01; mutated NPM1, P , .0001), OS (HSCT, P , .0001;
sHD group, P 5 .05; mutated NPM1, P 5 .0006), and RFS (HSCT, P , .0001; sHD group, P 5 .003; mutated NPM1, P 5 .007). All other factors did not reach statistical significance
(P . .05).
‡The ELN 2010 risk stratification incorporated: cytogenetics and genetics. In addition to the favorable risk class, the modified prognostic model identified significant associations for
improved CR (sHD group, P 5 .0004; age # 60 years, P 5 .03), OS (HSCT, P , .0001; sHD group, P 5 .003; no hepatosplenomegaly, P 5 .009; WBC, #50 3109/L, P 5 .02), and
RFS (HSCT, P , .0001; sHD group, P 5 .001; no hepatosplenomegaly, P 5 .0002; WBC, #50 3109/L, P 5 .02). All other factors did not reach statistical significance (P . .05).
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Overall, our present findings highlighted the inappropriateness of a
uniform postremission therapy, with HSCT as the sole therapeutic
option, among patients with aggressive disease behavior. In this
HR setting, and for AML in general, we might further improve results
by targeting specific molecular lesions.60,61
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